de Bruyn Guy, Adhikarla Haritha, Brackett Caroline K, Jia Yichen, Lakshmanane Premkumar, Mudrak Sarah V, Sawant Sheetal, Zhang Donghui, Chicz Roman M, Sridhar Saranya, Tomaras Georgia D, Seaton Kelly E
Sanofi Vaccines Research & Development, Swiftwater, PA, USA.
Department of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University, Durham, NC, USA.
NPJ Vaccines. 2025 Jul 13;10(1):153. doi: 10.1038/s41541-025-01203-z.
We included measurement of pre-existing immunity to human endemic coronaviruses (HCoV) in a Phase I/II study of SARS-CoV-2 spike protein vaccine candidates. A Binding Antibody Multiplex Assay measured HCoV-specific IgG to the receptor binding domain or full-length spike of human coronaviruses HKU1, 229E, NL63, and OC43. We found no evidence for the impact of HCoV antibodies on neutralizing and binding antibody responses to the candidate SARS-CoV-2 vaccines.
在一项针对新型冠状病毒 2 型（SARS-CoV-2）刺突蛋白候选疫苗的 I/II 期研究中，我们纳入了对人类地方性冠状病毒（HCoV）的既往免疫力的测量。一种结合抗体多重检测法测量了针对人类冠状病毒 HKU1、229E、NL63 和 OC43 的受体结合域或全长刺突的 HCoV 特异性 IgG。我们没有发现证据表明 HCoV 抗体对候选 SARS-CoV-2 疫苗的中和及结合抗体反应有影响。
